The Cerebral Protective Effect of Novel Erinacines from <i>Hericium erinaceus</i> Mycelium on In Vivo Mild Traumatic Brain Injury Animal Model and Primary Mixed Glial Cells via Nrf2-Dependent Pathways

<i>Hericium erinaceus</i>, a consumable mushroom, has shown a potential to enhance the production of neuroprotective bioactive metabolites. Traumatic brain injury (TBI) often leads to cognitive, physical, and psychosocial impairments, resulting in neuroinflammation and the loss of cortic...

Full description

Bibliographic Details
Main Authors: Kam-Fai Lee, Yung-Yu Hsieh, Shui-Yi Tung, Chih-Chuan Teng, Kung-Chuan Cheng, Meng-Chiao Hsieh, Cheng-Yi Huang, Ko-Chao Lee, Li-Ya Lee, Wan-Ping Chen, Chin-Chu Chen, Hsing-Chun Kuo
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Antioxidants
Subjects:
Online Access:https://www.mdpi.com/2076-3921/13/3/371
Description
Summary:<i>Hericium erinaceus</i>, a consumable mushroom, has shown a potential to enhance the production of neuroprotective bioactive metabolites. Traumatic brain injury (TBI) often leads to cognitive, physical, and psychosocial impairments, resulting in neuroinflammation and the loss of cortical neurons. In this research, the effects of <i>H. erinaceus</i> mycelium, its derivative erinacine C, along with the underlying mechanisms, were examined in terms of oxidative stress modulation and neurological improvement in a rat model of mild traumatic brain injury (mTBI). Male Sprague-Dawley rats were administered diets containing <i>H. erinaceus</i> mycelium and erinacine C following experimental brain injury; these supplements were continued throughout the recovery phase. The binding activity of NF-E2-related factor 2 (Nrf2) near antioxidant genes in mixed glial cells was measured by chromatin immunoprecipitation-quantitative polymerase chain reaction (ChIP-qPCR). The motor beam walking test revealed that dietary supplementation of <i>H. erinaceus</i> mycelium resulted in modest improvements in spatial memory while inhibiting neuron cell death and microglial activation according to brain histological examination. These findings were further corroborated by the upregulation of several antioxidant enzymes (catalase, glutathione reductase, thioredoxin reductase, and superoxide dismutase) and phospho-CAMP-response element-binding (p-CREB) levels in the mTBI model treated with <i>H. erinaceus</i> mycelium. Erinacine C treatment led to significantly reduced brain inflammation and normalization of mTBI-induced deficits through the modulation of the Nrf2 activation pathway and upregulated expression of numerous Nrf2-binding antioxidant genes such as catalase, thioredoxin reductase, superoxide dismutase, and brain-derived neurotrophic factor. This study demonstrates the potential of <i>H. erinaceus</i> mycelium and erinacine C in facilitating recovery following mTBI, including the prevention of neuronal injury and inactivation of microglia through the Nrf2-mediated antioxidant pathway in vivo.
ISSN:2076-3921